# Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

> **NCT03559543** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 40 (actual)

## Conditions studied

- Colorectal Neoplasm
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasm
- Rectal Diseases
- Colonic Diseases
- Intestinal Disease
- Gastrointestinal Disease
- Digestive System Disease

## Interventions

- **DIETARY_SUPPLEMENT:** Ocoxin-Viusid

## Key facts

- **NCT ID:** NCT03559543
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2022-06-30
- **Final completion:** 2024-01-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03559543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03559543, "Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03559543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*